

Metrics and Top Tips

Going green

Ann Sullivan
NWL CRN ID&M and Public Health Specialty Lead
BHIVA 2015



Recruitment to Time and Target for Open Study and Site Performance at 28 February 2015

RTT date = 28 Feb 2015

2	Study information													Site Information 67 study sites (as currently filtered) 4886 recruits year to date; 17667 in total									
	Division	Specialty	Com m?	IRAS ID	Study ID	Study Acronym / Short Title	Led by NWL?	Chief Investigator	Planned Recr Closure Date	National Target	National Recr to Date	National BRAG	Date of Last Upload	Trust Name	Local Investigator	NHS Permission	Local Target	Local Recr 2014	Local Recr to Date	% Recr Time Elapse	% Local Target Achiev	Local BRAG	
42	Division 6	Infectious disea	N	42869	9253	Study of transmission risk be	N	Prof Andrew Phillips	1/6/2017	840	472	-10%	10/3/2015	CandW	David Asboe	2/12/2010	122	18	132	65%	108%	43%	
43	Division 6	Infectious disea	N	42869	9253	Study of transmission risk be	N	Prof Andrew Phillips	1/6/2017	840	472	-10%	10/3/2015	Imperial	Dr Sarah Fidler	11/2/2011	10	0	8	64%	80%	16%	
44	Division 6	Infectious disea	N	9578	PANNA		Y	Dr Graham Taylor	31/12/2015	16	38	152%	13/3/2015	Imperial	Dr Graham Taylor	16/3/2010	5	0	9	86%	180%	94%	
45	Division 6	Infectious disea	N	9578	PANNA		Y	Dr Graham Taylor	31/12/2015	16	38	152%	13/3/2015	CandW	David Hawkins	17/11/2009	10	3	20	86%	200%	114%	
52	Division 6	Infectious disea	N	60227	10882	Defining risk factors for teno	N	Dr Frank Post	30/11/2015	50	62	41%	26/3/2015	CandW	Rachael Jones	26/4/2012	8	9	11	79%	138%	58%	
53	Division 6	Infectious disea	N	60227	10882	Defining risk factors for teno	N	Dr Frank Post	30/11/2015	50	62	41%	26/3/2015	Imperial	Dr Angela Bailey	3/5/2013	10	0	8	71%	80%	9%	
57	Division 6	Infectious disea	N	65080	11656	Azithromycin for the treatme	N	Dr Gillian Dean	1/5/2015	396	249	-32%	24/3/2015	CandW	Dr Michael Rayment	26/11/2014	22	0	0	60%	-	Black	
58	Division 6	Infectious disea	N	65080	11656	Azithromycin for the treatme	N	Dr Gillian Dean	1/5/2015	396	249	-32%	24/3/2015	Imperial	Dr Linda Greene	7/9/2012	50	8	39	94%	78%	-16%	
68	Division 6	Infectious disea	N	99557	12578	TAILoR	N	Prof Munir Pirmohamed	31/3/2015	282	302	11%	2/4/2015	CandW	Graeme Moyle	None	62	28	28	100%	45%	unavail	
	Division 6	Infectious disea	N	102430	12639	CSF Inflammatory Markers Aff	Y	Prof Brian Gazzard	31/5/2015	30	14	-44%	17/3/2015	CandW	Brian Gazzard	31/8/2012	60	4	14	91%	23%	-67%	
69	Division 6	Infectious disea	N	83975	12761	RSV & Flu Study	Y	Prof Peter Openshaw	31/10/2017	48	44	42%	5/1/2015	Imperial	Professor Peter Open	20/1/2012	36	0	44	54%	122%	68%	
71	Division 6	Infectious disea	Y	162422	18188	INFE 4003 (HIV) Sure Check H	N	Sr CCRN Industry Recruitment	31/5/2015	400	105	-25%	24/3/2015	CNWL	John Saunders	19/11/2014	400	0	0	52%	-	Black	
74	Division 6	Infectious disea	N	96554	13179	EVOHC/INTAPHIR	N	Prof Anna Maria Geretti	30/9/2015	455	32	-73%	25/3/2014	CandW	Mark Nelson	5/12/2012	1	0	10	79%	1000%	921%	
78	Division 6	Infectious disea	N	88548	13756	Valacyclovir in Delaying Anti	Y	Dr Simon Barton	17/6/2017	60	12	-11%	2/4/2015	Imperial	Dr Alan Winston	4/10/2013	10	0	0	38%	-	Black	
85	Division 6	Infectious disea	N	88548	13756	Valacyclovir in Delaying Anti	Y	Dr Simon Barton	17/6/2017	60	12	-11%	2/4/2015	CandW	Simon Barton	22/7/2013	20	7	11	41%	55%	14%	
86	Division 6	Infectious disea	N	119788	13780	Oral vs Intravenous Antibioti	N	Dr Matthew Scarborough	13/11/2015	650	594	18%	2/4/2015	LNWH	Dr Matthew Scarboro	4/2/2015	12	1	1	9%	8%	0%	
87	Division 6	Infectious disea	N	106078	13838	POPPY: Pharmacokinetic and	Y	Dr Alan Winston	1/10/2015	1900	909	-29%	1/4/2015	CandW	Marta Boffito	6/9/2013	760	126	215	72%	28%	-43%	
88	Division 6	Infectious disea	N	106078	13838	POPPY: Pharmacokinetic and	Y	Dr Alan Winston	1/10/2015	1900	909	-29%	1/4/2015	Imperial	Dr Alan Winston	21/3/2013	240	69	204	77%	85%	8%	
89	Division 6	Infectious disea	N	126600	14152	Clinical Characterisation Pro	N	Dr Malcolm Semple	28/2/2023	1	1	80%	17/2/2015	CandW	Derek Bell	17/10/2013	1	0	0	15%	-	Black	
95	Division 6	Infectious disea	N	126600	14152	Clinical Characterisation Pro	N	Dr Malcolm Semple	28/2/2023	1	1	80%	17/2/2015	Imperial		18/10/2013	0	0	0	15%	-	Black	
96	Division 6	Infectious disea	N	126600	14152	Clinical Characterisation Pro	N	Dr Malcolm Semple	28/2/2023	1	1	80%	17/2/2015	Hillingdon Hospital	A Thornley	25/10/2013	0	0	0	14%	-	Black	
97	Division 6	Infectious disea	N	126600	14152	Clinical Characterisation Pro	N	Dr Malcolm Semple	28/2/2023	1	1	80%	17/2/2015	WMUH		18/10/2013	0	0	0	15%	-	Black	
98	Division 6	Infectious disea	N	126600	14152	Clinical Characterisation Pro	N	Dr Malcolm Semple	28/2/2023	1	1	80%	17/2/2015	LNWH	Tariq Husain/Gopal R	25/10/2013	0	0	0	14%	0%	Black	
99	Division 6	Infectious disea	N	115303	14233	Attitudes to and Understandi	N	Dr alison rodger	31/12/2015	2,000	2,781	71%	10/3/2015	CandW	David Asboe	25/6/2013	500	546	990	67%	198%	131%	
104	Division 6	Infectious disea	Y	158100	17164	CCRN 2170 / HIV/AIDS Pandem	Y		1/12/2015	32	10	0%	2/4/2015	CandW	Dr Graeme Moyle	27/10/2014	2	8	8	21%	100%	260%	



*National Institute for
Health Research*

Clinical Research Network
Infectious diseases and microbiology

FIRST PARTICIPANT

Trust/DH Target = 70 DAYS

Recruit first participant within 70 calendar days of submission of a valid research application; essentially, submission of a signed SSI form in IRAS

Target is applicable to all studies at the Trust

Failure to achieve the 70 day target will result in financial penalties to the Trust in the future (although the mechanism remains unspecified)

LCRN Target = 30 DAYS

Only applies to portfolio studies

First participant nationally to be recruited
within 30 calendar days of the first issued
NHS Permission (R&D approval)



*National Institute for
Health Research*

Clinical Research Network
Infectious diseases and microbiology

TIME AND TARGET

Time and Target

Take the recruitment target and study duration in submission (usually take upper number if range given) to give a monthly target

Measure performance against this

RAG rated

Time and Target for Open Study and Site Performance at 28 February 2015

RTT date = 28 Feb 2015

						Site Information 67 study sites (as currently filtered) 4886 recruits year to date; 17667 in total								
	Planned Recr Closure Date	National Target	National Recr to Date	National BRAG	Date of Last Upload	Trust Name	Local Investigator	NHS Permission	Local Target	Local Recr 2014-15	Local Recr to Date	% Recr Time Elapsed	% Local Target Achieved	Local BRAG
37	30/6/2015	2,000	2,629	38%	23/1/2015			18/2/2014	213	162	186	65%	87%	22%
42	1/6/2017	840	472	-10%	10/3/2015			2/12/2010	122	18	132	65%	108%	43%
43	1/6/2017	840	472	-10%	10/3/2015			11/2/2011	10	0	8	64%	80%	16%
44	31/12/2015	16	38	152%	13/3/2015			16/3/2010	5	0	9	86%	180%	94%
45	31/12/2015	16	38	152%	13/3/2015			17/11/2009	10	3	20	86%	200%	114%
52	30/11/2015	50	62	41%	26/3/2015			26/4/2012	8	9	11	79%	138%	58%
53	30/11/2015	50	62	41%	26/3/2015			3/5/2013	10	0	8	71%	80%	9%
57	1/5/2015	396	249	-32%	24/3/2015			26/11/2014	22	0	0	60%	-	
58	1/5/2015	396	249	-32%	24/3/2015			7/9/2012	50	8	39	94%	78%	-16%
68	31/3/2015	282	302	11%	2/4/2015			None	62	28	28	100%	45%	unavail
	31/5/2015	30	14	-44%	17/3/2015			31/8/2012	60	4	14	91%	23%	-67%
69														
71	31/10/2017	48	44	42%	5/1/2015			20/1/2012	36	0	44	54%	122%	68%

Effects

Reduce delays to setting up and initiating studies

Complete research in timely manner

Starting to

- link LCRN funding to performance rate researchers

- consider terminating poorly performing studies (Trusts)

Tips

Submission – IRAS/ethics

- be realistic

- don't give a range

Do a robust feasibility assessment (CI,PI)

Plan study start - only sign SSI when everything is in place

- all amendments approved

- pharmacy signed off*

- set up meetings (esp commercial)*

- if possible have ppts identified/ready to approach

*or dates arranged

Tips

Most studies will be red to start

Monitor performance and intervene early

Identify possible reasons and solutions

Consider additional sites

CRN support – local and national

Can revise both target and recruitment time – do proactively, need evidence of financial support, CI needs to notify central CRN

Funding

Devolved or LCRN or combination

Activity based funding, retrospective
Interventional:observational:large scale
14:3:1

Some CRNs are now introducing prospective
and performance elements as a proportion of
overall payment to Trusts

LCRN Support

‘technical/practical’ advice

flexible workforce –admin and research assistants/nurses (some Trust R+Ds)

held back funding – apply for in year financial support

identify new sites

PCPIE

HIDES I II III

	HIDES I	HIDES II	HIDES III
Dates	9/09-2/11	2011-2014	to 30/06/15
Type	feasibility pilot	main study	extension
Setting	Acute Trust Primary Care	Acute Trusts Primary Care	Acute Trust Primary Cares
UK sites AT + PC	1 +1	8 +1	1 + 7
# Indicator Conditions	8	11	1
#surveys	9	24	8
#patients	2629		